Cargando…
Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by specific vascular and obstetric manifestations and by antiphospholipid antibodies (aPL) positivity. Microvascular damage in the course of APS and “aPL carrier” patients without symptoms is poorly investigat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237465/ https://www.ncbi.nlm.nih.gov/pubmed/34176504 http://dx.doi.org/10.1186/s13075-021-02551-6 |
_version_ | 1783714734178041856 |
---|---|
author | Ferrari, Giorgia Gotelli, Emanuele Paolino, Sabrina Pesce, Giampaola Nanni, Luca Colombo, Barbara Maria Pacini, Greta Schenone, Carlotta Pizzorni, Carmen Sulli, Alberto Smith, Vanessa Cutolo, Maurizio |
author_facet | Ferrari, Giorgia Gotelli, Emanuele Paolino, Sabrina Pesce, Giampaola Nanni, Luca Colombo, Barbara Maria Pacini, Greta Schenone, Carlotta Pizzorni, Carmen Sulli, Alberto Smith, Vanessa Cutolo, Maurizio |
author_sort | Ferrari, Giorgia |
collection | PubMed |
description | BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by specific vascular and obstetric manifestations and by antiphospholipid antibodies (aPL) positivity. Microvascular damage in the course of APS and “aPL carrier” patients without symptoms is poorly investigated. OBJECTIVES: This study aims to compare nailfold videocapillaroscopy (NVC) microvascular parameters in APS patients and non-symptomatic "aPL carriers" and to investigate their possible correlations with different aPL subtypes. METHODS: NVC was performed during standard evaluations in 18 APS patients (mean age 50 ± 13.8 years), 24 "aPL carriers" without symptoms (mean age 46.4 ± 16.4 years), and 18 control patients (CTR) (mean age 74 ± 12.5 years) taking oral anticoagulants for non-immunological indications (i.e., cardiovascular accidents). All patients were investigated for the presence of dilated capillaries, giant capillaries, microhemorrhages, capillary loss, and further non-specific/specific abnormalities (i.e., branched “bushy” capillaries, sign of neoangiogenesis) by NVC. Every alteration was also classified according to a semi-quantitative score. Lupus anticoagulant, anticardiolipin antibodies, and antibeta2 glycoprotein I antibodies were tested in each patient. RESULTS: APS patients showed at NVC increased frequency of microhemorrhages (p = 0.039)—particularly a “comb-like” pattern (parallel hemorrhages) (p = 0.002)—than "aPL carriers". Of note, there were no significant differences concerning the isolated number of microhemorrhages between APS and the CTR group (p = 0.314), but “comb-like” hemorrhages were significantly more frequent in the APS group (p = 0.034). Not any significant correlation was found between the aPL subtypes and NVC parameters. CONCLUSIONS: APS patients showed significantly a greater number of non-specific NVC abnormalities than "aPL carriers", particularly the “comb-like” NVC pattern. Oral anticoagulants may represent a confounding factor for isolated microhemorrhages. Not any correlation was found between aPL subtypes and NVC parameters. Further investigations are needed to better characterize the microvascular endothelium damage induced by aPL. |
format | Online Article Text |
id | pubmed-8237465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82374652021-06-29 Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings Ferrari, Giorgia Gotelli, Emanuele Paolino, Sabrina Pesce, Giampaola Nanni, Luca Colombo, Barbara Maria Pacini, Greta Schenone, Carlotta Pizzorni, Carmen Sulli, Alberto Smith, Vanessa Cutolo, Maurizio Arthritis Res Ther Research Article BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by specific vascular and obstetric manifestations and by antiphospholipid antibodies (aPL) positivity. Microvascular damage in the course of APS and “aPL carrier” patients without symptoms is poorly investigated. OBJECTIVES: This study aims to compare nailfold videocapillaroscopy (NVC) microvascular parameters in APS patients and non-symptomatic "aPL carriers" and to investigate their possible correlations with different aPL subtypes. METHODS: NVC was performed during standard evaluations in 18 APS patients (mean age 50 ± 13.8 years), 24 "aPL carriers" without symptoms (mean age 46.4 ± 16.4 years), and 18 control patients (CTR) (mean age 74 ± 12.5 years) taking oral anticoagulants for non-immunological indications (i.e., cardiovascular accidents). All patients were investigated for the presence of dilated capillaries, giant capillaries, microhemorrhages, capillary loss, and further non-specific/specific abnormalities (i.e., branched “bushy” capillaries, sign of neoangiogenesis) by NVC. Every alteration was also classified according to a semi-quantitative score. Lupus anticoagulant, anticardiolipin antibodies, and antibeta2 glycoprotein I antibodies were tested in each patient. RESULTS: APS patients showed at NVC increased frequency of microhemorrhages (p = 0.039)—particularly a “comb-like” pattern (parallel hemorrhages) (p = 0.002)—than "aPL carriers". Of note, there were no significant differences concerning the isolated number of microhemorrhages between APS and the CTR group (p = 0.314), but “comb-like” hemorrhages were significantly more frequent in the APS group (p = 0.034). Not any significant correlation was found between the aPL subtypes and NVC parameters. CONCLUSIONS: APS patients showed significantly a greater number of non-specific NVC abnormalities than "aPL carriers", particularly the “comb-like” NVC pattern. Oral anticoagulants may represent a confounding factor for isolated microhemorrhages. Not any correlation was found between aPL subtypes and NVC parameters. Further investigations are needed to better characterize the microvascular endothelium damage induced by aPL. BioMed Central 2021-06-27 2021 /pmc/articles/PMC8237465/ /pubmed/34176504 http://dx.doi.org/10.1186/s13075-021-02551-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ferrari, Giorgia Gotelli, Emanuele Paolino, Sabrina Pesce, Giampaola Nanni, Luca Colombo, Barbara Maria Pacini, Greta Schenone, Carlotta Pizzorni, Carmen Sulli, Alberto Smith, Vanessa Cutolo, Maurizio Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title | Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title_full | Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title_fullStr | Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title_full_unstemmed | Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title_short | Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
title_sort | antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237465/ https://www.ncbi.nlm.nih.gov/pubmed/34176504 http://dx.doi.org/10.1186/s13075-021-02551-6 |
work_keys_str_mv | AT ferrarigiorgia antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT gotelliemanuele antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT paolinosabrina antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT pescegiampaola antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT nanniluca antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT colombobarbaramaria antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT pacinigreta antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT schenonecarlotta antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT pizzornicarmen antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT sullialberto antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT smithvanessa antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings AT cutolomaurizio antiphospholipidantibodiesandanticoagulanttherapycapillaroscopicfindings |